Product Information

HYZAAR 100-25 TABLET is a brand product labeled by Organon LLC, priced at $6.8123 per EA under NDC 78206014101. Its NADAC has been published 248 times since Feb 23, 2022.

FDA first approved this application on Apr 28, 1995. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the losartan potassium and hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

HYZAAR 100-25 TABLET

losartan potassium and hydrochlorothiazide
$6.8123per EA
High Outlier

Strength

25; 100 mg/1; mg/1

Manufacturer

Organon LLC

NDC

78206014101

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

11/18/2026

Approval Type

New Drug (NDA)

FDA Application

NDA020387

FDA Approved

4/28/1995

TE Code

AB

On Market Since

6/1/2021

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for HYZAAR 100-25 TABLET has been published 248 times since Feb 23, 2022, and over the history we have for it it has risen 21.8%. The table below summarizes its recorded NADAC range and movement.

Current price$6.8123 per EA
All-time high$6.8321 (Sep 16, 2026)
All-time low$5.5924 (Feb 23, 2022)
52-week high$6.8321
52-week low$6.4948
Median price$6.1873
Average price$6.2231
Largest weekly change+6.0% (Jan 18, 2023)
Weeks tracked248
Tracking sinceFeb 23, 2022

Price History

1W

0.0%

1M

+0.2%

3M

-0.3%

6M

-0.1%

1Y

+4.9%

3Y

+11.1%

5Y

N/A

All

+21.8%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of HYZAAR 100-25 TABLET?

The current National Average Drug Acquisition Cost (NADAC) for HYZAAR 100-25 TABLET, manufactured by Organon LLC, is $6.8123 per EA (NDC 78206014101), effective Nov 18, 2026.

How has the price of HYZAAR 100-25 TABLET changed over time?

Over the history we have for it, the NADAC for HYZAAR 100-25 TABLET has risen 21.8%. It has been tracked across 248 weekly CMS publications since Feb 23, 2022.

What are the highest and lowest recorded NADAC prices for HYZAAR 100-25 TABLET?

Since Feb 23, 2022, the NADAC for HYZAAR 100-25 TABLET has ranged from a low of $5.5924 (Feb 23, 2022) to a high of $6.8321 (Sep 16, 2026), with a median of $6.1873 per EA.

Are there cheaper alternatives to HYZAAR 100-25 TABLET?

Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LOSARTAN-HYDROCHLOROTHIAZIDE 100-25 MG TAB, is $0.0776 per EA — about 99% below HYZAAR 100-25 TABLET.

Who manufactures HYZAAR 100-25 TABLET?

HYZAAR 100-25 TABLET (NDC 78206014101) is labeled by Organon LLC, and CMS classifies it as a brand product.